326 related articles for article (PubMed ID: 27435529)
1. Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure.
Netuka I; Kvasnička T; Kvasnička J; Hrachovinová I; Ivák P; Mareček F; Bílková J; Malíková I; Jančová M; Malý J; Sood P; Sundareswaran KS; Connors JM; Mehra MR
J Heart Lung Transplant; 2016 Jul; 35(7):860-7. PubMed ID: 27435529
[TBL] [Abstract][Full Text] [Related]
2. Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial.
Bansal A; Uriel N; Colombo PC; Narisetty K; Long JW; Bhimaraj A; Cleveland JC; Goldstein DJ; Stulak JM; Najjar SS; Lanfear DE; Adler ED; Dembitsky WP; Somo SI; Crandall DL; Chen D; Connors JM; Mehra MR
J Heart Lung Transplant; 2019 Aug; 38(8):806-816. PubMed ID: 31147187
[TBL] [Abstract][Full Text] [Related]
3. Reduced continuous-flow left ventricular assist device speed does not decrease von Willebrand factor degradation.
Kang J; Zhang DM; Restle DJ; Kallel F; Acker MA; Atluri P; Bartoli CR
J Thorac Cardiovasc Surg; 2016 Jun; 151(6):1747-1754.e1. PubMed ID: 26971377
[TBL] [Abstract][Full Text] [Related]
4. Left Ventricular Assist Device Design Reduces von Willebrand Factor Degradation: A Comparative Study Between the HeartMate II and the EVAHEART Left Ventricular Assist System.
Bartoli CR; Kang J; Zhang D; Howard J; Acker M; Atluri P; Motomura T
Ann Thorac Surg; 2017 Apr; 103(4):1239-1244. PubMed ID: 27717422
[TBL] [Abstract][Full Text] [Related]
5. Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump.
Goda M; Jacobs S; Rega F; Peerlinck K; Jacquemin M; Droogne W; Vanhaecke J; Van Cleemput J; Van den Bossche K; Meyns B
J Heart Lung Transplant; 2013 May; 32(5):539-45. PubMed ID: 23570742
[TBL] [Abstract][Full Text] [Related]
6. Acquired von Willebrand factor deficiency is reduced in HeartMate 3 patients†.
Klaeske K; Dieterlen MT; Scholz U; Lehmann S; Garbade J; Fischer J; Jawad K; Borger MA; Meyer A
Eur J Cardiothorac Surg; 2019 Sep; 56(3):444-450. PubMed ID: 30815698
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of von Willebrand factor profiles in pulsatile and continuous left ventricular assist device recipients.
Crow S; Milano C; Joyce L; Chen D; Arepally G; Bowles D; Thomas W; Ortiz NV
ASAIO J; 2010; 56(5):441-5. PubMed ID: 20613494
[TBL] [Abstract][Full Text] [Related]
8. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device.
Meyer AL; Malehsa D; Budde U; Bara C; Haverich A; Strueber M
JACC Heart Fail; 2014 Apr; 2(2):141-5. PubMed ID: 24720921
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ADAMTS-13 by Doxycycline Reduces von Willebrand Factor Degradation During Supraphysiological Shear Stress: Therapeutic Implications for Left Ventricular Assist Device-Associated Bleeding.
Bartoli CR; Kang J; Restle DJ; Zhang DM; Shabahang C; Acker MA; Atluri P
JACC Heart Fail; 2015 Nov; 3(11):860-9. PubMed ID: 26454844
[TBL] [Abstract][Full Text] [Related]
10. In vitro comparison of the hemocompatibility of two centrifugal left ventricular assist devices.
Zayat R; Moza A; Grottke O; Grzanna T; Fechter T; Motomura T; Schmidt-Mewes C; Breuer T; Autschbach R; Rossaint R; Goetzenich A; Bleilevens C
J Thorac Cardiovasc Surg; 2019 Feb; 157(2):591-599.e4. PubMed ID: 30414772
[TBL] [Abstract][Full Text] [Related]
11. A Novel Toroidal-Flow Left Ventricular Assist Device Minimizes Blood Trauma: Implications of Improved Ventricular Assist Device Hemocompatibility.
Bartoli CR; Hennessy-Strahs S; Gohean J; Villeda M; Larson E; Longoria R; Kurusz M; Acker MA; Smalling R
Ann Thorac Surg; 2019 Jun; 107(6):1761-1767. PubMed ID: 30586577
[TBL] [Abstract][Full Text] [Related]
12. Decreased RPM reduces von Willebrand factor degradation with the EVAHEART LVAS: implications for device-specific LVAD management.
Bartoli CR; Kang J; Motomura T
J Card Surg; 2020 Jul; 35(7):1477-1483. PubMed ID: 32652785
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Models for Translational Investigations of Left Ventricular Assist Device-Associated von Willebrand Factor Degradation.
Restle DJ; Zhang DM; Hung G; Howard JL; Kallel F; Acker MA; Atluri P; Bartoli CR
Artif Organs; 2015 Jul; 39(7):569-75. PubMed ID: 25810063
[TBL] [Abstract][Full Text] [Related]
14. Influence of a Rotational Speed Modulation System Used With an Implantable Continuous-Flow Left Ventricular Assist Device on von Willebrand Factor Dynamics.
Naito N; Mizuno T; Nishimura T; Kishimoto S; Takewa Y; Eura Y; Kokame K; Miyata T; Date K; Umeki A; Ando M; Ono M; Tatsumi E
Artif Organs; 2016 Sep; 40(9):877-83. PubMed ID: 26750507
[TBL] [Abstract][Full Text] [Related]
15. Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent.
Jilma-Stohlawetz P; Quehenberger P; Schima H; Stoiber M; Knöbl P; Steinlechner B; Felli A; Jilma B
Thromb Res; 2016 Jan; 137():196-201. PubMed ID: 26616301
[TBL] [Abstract][Full Text] [Related]
16. Speed Reduction Does Not Restore High Molecular Weight von Willebrand Multimers During HeartMate II Support: An In Vivo Study.
Saeed O; Rangasamy S; Reyes Gil M; Goldstein DJ; Billett HH; Jorde UP; Patel SR
ASAIO J; 2018; 64(5):e123-e125. PubMed ID: 29863626
[TBL] [Abstract][Full Text] [Related]
17. Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients.
Joyce D; Crow S; Li Z; Joyce L; Milano C; Rogers J; Villamizar-Ortiz N; Chen D
J Heart Lung Transplant; 2012 Jul; 31(7):750-6. PubMed ID: 22538169
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a mathematical model for evaluating shear-induced damage of von Willebrand factor.
Li Y; Xi Y; Wang H; Sun A; Wang L; Deng X; Chen Z; Fan Y
Comput Biol Med; 2023 Sep; 164():107379. PubMed ID: 37597407
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of von Willebrand factor profiles after implantation of left ventricular assist device and total artificial heart.
Reich HJ; Morgan J; Arabia F; Czer L; Moriguchi J; Ramzy D; Esmailian F; Lam L; Dunhill J; Volod O
J Thromb Haemost; 2017 Aug; 15(8):1620-1624. PubMed ID: 28586149
[TBL] [Abstract][Full Text] [Related]
20. Effects of HeartWare ventricular assist device on the von Willebrand factor: results of an academic Belgian center.
Esmaeilzadeh F; Wauters A; Wijns W; Argacha JF; van de Borne P
BMC Cardiovasc Disord; 2016 Aug; 16(1):155. PubMed ID: 27485105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
